TKI-话题@MedSci

#TKI#

128篇内容 | 2058人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384146, encodeId=d6a713841467a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, objectType=article, longId=35713, objectId=eb7735e1356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7735e1356, replyNumber=0, likeNumber=40, createdTime=2014-06-02, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7735e1356, moduleTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7735e1356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384142, encodeId=8d8f13841424c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, objectType=article, longId=19401, objectId=650819401a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=650819401a2, replyNumber=0, likeNumber=44, createdTime=2013-05-30, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=650819401a2, moduleTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=650819401a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384141, encodeId=ecc3138414147, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=晚期非小细胞肺癌EGFR-TKI失败后治疗策略, objectType=article, longId=19179, objectId=ca42191e93e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca42191e93e, replyNumber=0, likeNumber=48, createdTime=2013-05-24, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca42191e93e, moduleTitle=晚期非小细胞肺癌EGFR-TKI失败后治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca42191e93e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384140, encodeId=cde3138414020, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响, objectType=article, longId=19006, objectId=445d1900630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=445d1900630, replyNumber=0, likeNumber=45, createdTime=2013-05-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=445d1900630, moduleTitle=ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=445d1900630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384139, encodeId=892a138413977, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=BIM多态性与TKI耐药, objectType=article, longId=5021, objectId=9d065021e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d065021e7, replyNumber=0, likeNumber=30, createdTime=2012-04-13, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d065021e7, moduleTitle=BIM多态性与TKI耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d065021e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384138, encodeId=4b26138413855, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Nat Med：发现东亚人TKI耐受原因, objectType=article, longId=4959, objectId=306349599d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306349599d, replyNumber=0, likeNumber=57, createdTime=2012-04-12, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306349599d, moduleTitle=Nat Med：发现东亚人TKI耐受原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306349599d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384137, encodeId=fd40138413edf, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Nat Med：BIM基因变异可能是东亚人对TKI耐受原因, objectType=article, longId=4402, objectId=98b24402bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98b24402bb, replyNumber=0, likeNumber=35, createdTime=2012-03-25, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98b24402bb, moduleTitle=Nat Med：BIM基因变异可能是东亚人对TKI耐受原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98b24402bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384136, encodeId=9d591384136ea, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=克服肺癌EGFR-TKI耐药的新方法, objectType=article, longId=3782, objectId=d35d3e8239, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d35d3e8239, replyNumber=0, likeNumber=38, createdTime=2012-01-27, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d35d3e8239, moduleTitle=克服肺癌EGFR-TKI耐药的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d35d3e8239)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384135, encodeId=4827138413583, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析, objectType=article, longId=3780, objectId=8ee93e804e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee93e804e, replyNumber=0, likeNumber=0, createdTime=2012-01-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee93e804e, moduleTitle=HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee93e804e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384134, encodeId=4e0c138413470, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=王洁：克服EGFR-TKI耐药的新方法, objectType=article, longId=3196, objectId=e919319619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e919319619, replyNumber=0, likeNumber=38, createdTime=2011-10-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e919319619, moduleTitle=王洁：克服EGFR-TKI耐药的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e919319619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384133, encodeId=2a9b1384133f8, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSCO 2011:EGFRTKI敏感与耐药肺癌细胞信号通路表达差异的探讨, objectType=article, longId=3112, objectId=5cde3112ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cde3112ec, replyNumber=0, likeNumber=38, createdTime=2011-09-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cde3112ec, moduleTitle=CSCO 2011:EGFRTKI敏感与耐药肺癌细胞信号通路表达差异的探讨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cde3112ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著

2014-06-02

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况

2013-05-30

lsj628 (审核中...)

前往app查看评论内容

#TKI#

晚期非小细胞肺癌EGFR-TKI失败后治疗策略

2013-05-24

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响

2013-05-22

lsj628 (审核中...)

前往app查看评论内容

#TKI#

BIM多态性与TKI耐药

2012-04-13

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Nat Med：发现东亚人TKI耐受原因

2012-04-12

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Nat Med：BIM基因变异可能是东亚人对TKI耐受原因

2012-03-25

lsj628 (审核中...)

前往app查看评论内容

#TKI#

克服肺癌EGFR-TKI耐药的新方法

2012-01-27

zhaojie88 (审核中...)

前往app查看评论内容

#TKI#

HER2阳性转移性乳腺癌TKI治疗基于分子标志物的预后及疗效分析

2012-01-27

lsj628 (审核中...)

前往app查看评论内容

#TKI#

王洁：克服EGFR-TKI耐药的新方法

2011-10-17

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSCO 2011:EGFRTKI敏感与耐药肺癌细胞信号通路表达差异的探讨

2011-09-17

科室
- - 订阅+
  - 更多科室
工具
服务